Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
|
Overview of Myelodysplastic Syndromes with Focus on Iron
Myelodysplastic syndromes are a heterogeneous group of haematologic neoplasias with complex diagnostic and prognostic classifications. In this webcast, Dr. Norbert Gattermann lays the foundation for a clearer understanding of MDS by explaining its pathophysiology, the distinctions between lower-risk and higher-risk disease, and the mechanisms for iron overload. A central question in this presentation is how risk level influences treatment options, including chelation therapy.
|
|
Faculty
|
|
|
Norbert Gattermann, MD, PhD
Department of Haematology,
Oncology and Clinical Immunology
Heinrich-Heine-University
Dusseldorf, Germany
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases.
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Apply knowledge of the pathophysiology of myelodysplastic syndromes to identify the mechanisms of iron overload in patients with myelodysplastic syndromes.
- Evaluate the role of disease risk level in determining treatment options, including chelation therapy, in patients with myelodysplastic syndromes.
|
Disclosure Information
Norbert Gattermann, MD, PhD, is on the speakers bureau of and on the advisory boards for Novartis Pharmaceuticals Corporation and Pharmion Corporation. Prof. Gatterman has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
